{"id":"W2756719694","doi":"10.1200/jco.2017.35.15_suppl.tps7577","title":"CheckMate 436: A phase 1-2 study to evaluate safety and efficacy of nivolumab plus brentuximab vedotin in patients with CD30-expressing relapsed/refractory non-Hodgkin lymphomas.","year":2017,"lang":"en","type":"article","venue":"Journal of Clinical Oncology","topic":"Lymphoma Diagnosis and Treatment","field":"Medicine","cited_by":0,"is_retracted":false,"has_abstract":true,"ca_institutions":"Princess Margaret Cancer Centre; BC Cancer Agency","funders":"","keywords":"Brentuximab vedotin; Medicine; Nivolumab; CD30; Mycosis fungoides; Anaplastic large-cell lymphoma; Lymphoma; Internal medicine; Oncology; Cancer research; Immunotherapy; Cancer","routes":{"ca_aff":true,"ca_fund":false,"ca_venue":false,"about_ca":false,"invisible_to_affiliation_only":false},"retraction":null,"screen":null,"direct_labels":[],"prediction":{"model_version":"metacan-v3-hybrid-931329e0061c","candidate_categories":[],"consensus_categories":[],"category_scores_codex":[0.001992488,0.001296186,0.002123407,0.0005483694,0.0003623131,0.001055036,0.001172977,0.001301944,0.006530344],"category_scores_gemma":[0.001034571,0.0007339659,0.001547733,0.000472344,0.0007579528,0.0008557739,0.000403447,0.00232553,0.001103666],"about_ca_system_candidate":false,"about_ca_system_consensus":false,"about_ca_system_score_codex":0.00141705,"about_ca_system_score_gemma":0.001618873,"about_ca_topic_candidate":false,"about_ca_topic_consensus":false,"about_ca_topic_score_codex":0.001185195,"about_ca_topic_score_gemma":0.003380276,"domain_scores_codex":[0.9995432,0.0002210644,0.0000249357,0.00008348707,0.00005745517,0.000069973],"domain_scores_gemma":[0.9992847,0.0001078369,0.0001542058,0.00004793888,0.00004210659,0.0003633675],"domain_codex":null,"domain_gemma":null,"domain_candidate":null,"domain_consensus":null,"study_design_codex":"randomized_trial","study_design_gemma":"nonrandomized_trial","study_design_scores_codex":[0.8069329,0.0627998,0.009223357,0.001521744,0.002017834,0.0004068639,0.0002414772,0.00201898,0.03275684,0.0002800485,0.003687369,0.07811279],"study_design_scores_gemma":[0.5731586,0.4054945,0.01337563,0.00004915447,0.0007576909,0.0003580341,0.00004151291,0.00105772,0.002342717,0.0001398994,0.003190057,0.00003455413],"study_design_candidate":"nonrandomized_trial","study_design_consensus":null,"genre_codex":"empirical","genre_gemma":"empirical","genre_scores_codex":[0.9851509,0.003403658,0.0007507769,0.0003346145,0.0001282535,0.005423126,0.002509678,0.0001523235,0.002146616],"genre_scores_gemma":[0.9832917,0.002069607,0.002220506,0.001217293,0.0002024232,0.004214463,0.003952456,0.00004514648,0.002786442],"genre_candidate":"empirical","genre_consensus":"empirical","teacher_disagreement_score":0.006530344,"threshold_uncertainty_score":0.02184618,"prediction_status":"machine_predicted_unvalidated"},"machine_scores":{"provisional":true,"baseline":true,"maturity_gate_passed":false,"score_opus":0.06945349368179177,"score_gpt":0.4527450427705728,"score_spread":0.383291549088781,"validation_status":"score_only:v0-immature-baseline","note":"Baseline scores from an immature model (maturity gate not passed). Scores rank; they never assert a category."}}